Compare NBIX & WY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | WY |
|---|---|---|
| Founded | 1992 | 1900 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 17.7B |
| IPO Year | 1996 | 1994 |
| Metric | NBIX | WY |
|---|---|---|
| Price | $155.12 | $23.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 7 |
| Target Price | ★ $180.91 | $28.86 |
| AVG Volume (30 Days) | 1.1M | ★ 4.5M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.46% |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 3.30 | 0.44 |
| Revenue | $161,626,000.00 | ★ $6,905,000,000.00 |
| Revenue This Year | $24.73 | $5.78 |
| Revenue Next Year | $13.14 | $8.94 |
| P/E Ratio | ★ $47.95 | $52.65 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $21.16 |
| 52 Week High | $186.12 | $27.75 |
| Indicator | NBIX | WY |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 36.31 |
| Support Level | $153.96 | $22.54 |
| Resistance Level | $161.29 | $25.14 |
| Average True Range (ATR) | 3.58 | 0.50 |
| MACD | 0.90 | -0.16 |
| Stochastic Oscillator | 77.56 | 12.83 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.